Jiangxi Fushine Pharmaceutical Co Ltd
SZSE:300497
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/S
Price to Sales (P/S) ratio shows how much investors pay for each dollar of a company`s sales. It`s calculated by dividing the company`s market value by its total revenue.
Price to Sales (P/S) ratio shows how much investors pay for each dollar of a company`s sales. It`s calculated by dividing the company`s market value by its total revenue.
Valuation Scenarios
If P/S returns to its 3-Year Average (4.2), the stock would be worth ¥7.64 (60% downside from current price).
| Scenario | P/S Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 10.7 | ¥19.32 |
0%
|
| 3-Year Average | 4.2 | ¥7.64 |
-60%
|
| 5-Year Average | 4.4 | ¥7.85 |
-59%
|
| Industry Average | 3.9 | ¥7.09 |
-63%
|
| Country Average | 2.8 | ¥4.98 |
-74%
|
Forward P/S
Today’s price vs future revenue
| Today's Market Cap | Revenue | Forward P/S | ||
|---|---|---|---|---|
|
¥9.9B
|
/ |
Oct 2025
¥970.3m
|
= |
|
|
¥9.9B
|
/ |
Dec 2025
¥1.2B
|
= |
|
|
¥9.9B
|
/ |
Dec 2026
¥1.5B
|
= |
|
|
¥9.9B
|
/ |
Dec 2027
¥1.7B
|
= |
|
Forward P/S shows whether today’s P/S still looks high or low once future revenue are taken into account.
Peer Comparison
| Market Cap | P/S | P/E | ||||
|---|---|---|---|---|---|---|
| CN |
J
|
Jiangxi Fushine Pharmaceutical Co Ltd
SZSE:300497
|
10.4B CNY | 10.7 | -38.2 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
908.9B USD | 12.6 | 36 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
547.1B USD | 5.7 | 26 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 4.2 | 20.1 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
209.6B GBP | 4.7 | 27.4 | |
| CH |
|
Novartis AG
SIX:NOVN
|
221.1B CHF | 5 | 20.7 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
277.6B USD | 4.2 | 31.1 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | 105.4 | -83.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.2T DKK | 4 | 12.1 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
149.7B USD | 2.4 | 19.3 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
118.9B USD | 407.7 | 4 516.9 |
Market Distribution
| Min | 0 |
| 30th Percentile | 1.5 |
| Median | 2.8 |
| 70th Percentile | 5.4 |
| Max | 5 034 353.9 |
Other Multiples
Jiangxi Fushine Pharmaceutical Co Ltd
Glance View
Jiangxi Fushine Pharmaceutical Co., Ltd. engages in the research and development, manufacture, and sale of active pharmaceutical ingredient (API) and pharmaceutical intermediates. The company is headquartered in Jingdezhen, Jiangxi and currently employs 1,849 full-time employees. The company went IPO on 2015-12-22. The firm's main products include sulbactam series enzyme inhibitor bulk drugs, pharmaceutical intermediates and related products, tazobactam series enzyme inhibitor bulk drugs, pharmaceutical intermediates and related products, as well as intermediates of carbapenems bulk drugs. The firm distributes its products within domestic markets and to overseas markets, including European Union (EU) and other countries and regions in Asia.
